ClinicalTrials.gg
RecruitingNCT06496308Updated Jul 11, 2024

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

A Phase 3 interventional study of Orelabrutinib and Bendamustine in Mantle Cell Lymphoma (MCL), sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Ruijin Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell — 8 open to participants now, 8 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Mantle-Cell.

Planned enrollment
3rd of 10
78 · median 42
Started
2024
with 2 others
Phase 3
3 of 10
2 open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Ruijin Hospital

Among the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 4th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

8 of the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This multicenter, open-label, randomized controlled trial aims to evaluate the efficacy and safety of Orelabrutinib in combination with Bendamustine and Rituximab (OBR) versus Bendamustine and Rituximab (BR) in patients with intermediate- to high-risk mantle cell lymphoma (MCL) who are ineligible for transplantation. The primary objective is to assess the complete response (CR) rate during the induction phase, with secondary objectives including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Exploratory analysis will investigate the correlation between tumor biomarkers and treatment efficacy.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with MCL (mantle cell lymphoma) through flow cytometry or histopathology, and has not received prior treatment.
  • Age > 18 years of age, both genders are eligible.
  • Ann Arbor stage II-IV; for stage II subjects, those who require systemic therapy based on the investigator's judgment are eligible.
  • At least one .
  • (ECOG) performance status score of 0-2.
  • Any one of the following high-risk factors is present: MIPI score of 4-11, Ki67 > 50%, TP53 abnormality, blastic or pleomorphic variation.
  • Patients who are not suitable candidates for hematopoietic stem cell transplantation.
  • Laboratory tests (blood routine, liver and kidney function) meet the following requirements: a) Blood routine: White blood cell count ≥3.0×10\^9/L, ≥1.5×10\^9/L, ≥90g/L, count ≥75×10\^9/L. b) Liver function: Transaminases ≤2.5 times the , ≤1.5 times the upper limit of normal. c) Serum creatinine 44-133 mmol/L.
  • The investigator judges that the subject's is greater than 12 weeks from the time of screening.
  • Willing and able to participate in all required assessments and procedures of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received treatment with BTK inhibitors.
  • Patients with severe complications or serious infections.
  • Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.
  • Patients with active infections requiring systemic treatment, including bacterial, fungal, and viral infections.
  • -infected individuals.
  • Patients with mental disorders or those who are known or suspected to be unable to fully comply with the study protocol.
  • Patients whom the investigator judges to have other conditions that make them unsuitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib + Bendamustine + Rituximab (OBR)

    In induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in OBR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, and orelabrutinib 150mg/day PO once daily, every 28 day per cycle for 6 cycles.

    Drug: Orelabrutinib · Drug: Bendamustine · Drug: Rituximab

  • Placebo comparator
    Bendamustine + Rituximab (BR)

    In induction phase, patients will be randomized in two groups, one is OBR and another is BR. Patients in BR group will receive rituximab 375 mg/m² IV on day 1, bendamustine 90 mg/m² IV on day 1 and 2, every 28 day per cycle for 6 cycles.

    Drug: Bendamustine · Drug: Rituximab

  • Other
    Orelabrutinib + Venetoclax (OV)

    In maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients with TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily and venetoclax for up to 2 years, the dosing of Venetoclax is escalated gradually to reach a target dose of 400 mg.

    Drug: Orelabrutinib · Drug: Venetoclax

  • Other
    Orelabrutinib (O)

    In maintanance phase, patients will receive different medical regimen according to their TP53 mutation and blastic and pleomorphic variants status. Patients without TP53 mutation or blastic and/or pleomorphic variant will receive orelabrutinib 150mg/day PO once daily for up to 2 years.

    Drug: Orelabrutinib

Interventions

  • Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

  • Bendamustine IV will be administered as per the schedule specified in the respective arm.

  • Rituximab IV will be administered as per the schedule specified in the respective arm.

  • Venetoclax PO will be administered as per the schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Complete response rate

    Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: End of induction treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]

Secondary outcomes

  1. Overall Response Rate

    Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: End of induction treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]

  2. Progression-free survival

    Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  3. Overall survival

    Overall survival was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jul 2027, 36 months later.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartEst.
Jul 10, 2024
Primary completionEst.
Jul 10, 2027
CompletionEst.
Jul 10, 2027
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06496308
Lead sponsor
Ruijin Hospital
Collaborators
Third Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Fujian Medical University Union Hospital, Yantai Yuhuangding Hospital, Huadong Hospital Affiliated with Fudan University, Shanghai, The First Affiliated Hospital of Anhui Medical University, Jiangxi Provincial Cancer Hospital, Fujian Cancer Hospital
Responsible party
Zhao Weili (First Deputy Director, Hematology Department, Ruijin Hospital) — Principal investigator
First posted
Jul 11, 2024
Start date
Jul 10, 2024 (estimated)
Primary completion
Jul 10, 2027 (estimated)
Completion
Jul 10, 2027 (estimated)
Last update
Jul 11, 2024

Study contacts

Weili Zhao
Contact
zhao.weili@yahoo.com
+862164370045 ext. 610707
Li Wang
Contact
wl11194@rjh.com.cn
+862164370045 ext. 610707

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Orelabrutinib · Bendamustine · Rituximab

Start the discussion